Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: Is this the key to prevent severe adverse reactions following immunization?

Clinical and Experimental Immunology

Volumn 148, Issue 1, 2007, Pages 90-100

  Martins, M A ^a,b   Silva, M L ^a,b   Marciano, A P V ^a   Peruhype Magalhaes V ^a   Eloi Santos, S M ^a,b   Ribeiro, J G L ^c   Correa Oliveira, R ^a   Homma, A ^a   Kroon, E G ^b   Teixeira Carvalho, A ^a,d   Martins Filho, O A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c SES   (Brazil)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

17DD vaccination; Flow cytometry; Lymphocyte subsets; Yellow fever

Indexed keywords

CD19 ANTIGEN; CD32 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10 RECEPTOR; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE SUBPOPULATION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION; YELLOW FEVER;

ADULT; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MIDDLE AGED; YELLOW FEVER VACCINE;

EID: 33847644905     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03317.x     Document Type: Article

References (42)

1. Vasconcelos PF. Yellow fever: reflections on the disease, prospects for the century and risk of re-urbanization. Braz J Epidemiol 2002; 5:244-58.
2. Massad E, Coutinho FAB, Burattini MN, Lopez LF. The risk of yellow fever in dengue infested area. Trans R Soc Trop Med Hyg 2001; 95:370-4.
3. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65:787-800.
4. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34:1369-78.
5. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO 1981; 59:895-900.
6. Reinhardt B, Jaspeert Niedrig M, Kostner C, L'age-stehr J. Development of viremia and activation after vaccination with Yellow fever virus strain 17D: a model of human flavivirus infection. J Med Vir 1998; 56:159-67.
7. Hacker UT, Jelinek T, Erhardt S et al. In vivo synthesis of tumor necrosis factor-α in healthy human after yellow fever vaccination. J Infect Dis 1998; 177:774-8.
8. Co MDT, Terajima M, Cruz J, Ennis FA, Rothhman AL. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B335-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 2002; 293:151-63.
9. Centers for disease Control (CDC). Adverse events associated with 17D-derived yellow fever vaccination. United States, 2000-02. MMWR 2002; 51:989-93.
10. Stefano I, Sato HK, Pannuti CS et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 1999; 17:1042-6.
11. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
12. http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=21545.
13. Vasconcelos P, Luna E, Galler R et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Brazilian Yellow Fever Vaccine Evaluation Group. Lancet 2001; 358:91-7.
14. Rousset F, Garcia E, Defrance T et al. IL-10 is a potent growth and differentiation factor for human B lymphocytes. Proc Natl Acad Sci USA 1992; 89:1890-3.
15. Malisan F, Briere F, Bridon JM et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med 1996; 183:937-47.
16. Levy Y, Broue TJC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994; 93:424-8.
17. Kirschbaum J, Forschner K, Rasche C, Worm M. Modulation of lymphocyte phenotype and function by immunoglobulins. Br J Dermatol 2006; 154:225-30.
18. Daeron M, Latour S, Malbec O et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3:635-46.
19. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JVLA. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994; 369:340.
20. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-5.
21. Cassis L, Aiello S, Noris M. Natural versus adaptive regulatory T cells. Contrib Nephrol 2005; 146:121-31.
22. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target Cell death. Immunity 2004; 21:589-601.
23. Dittmer U, He H, Messer RJ et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 2004; 20:293-303.
24. + and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004; 112:258-67.
25. de Waal MR, Haanen J, Spits H et al. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presentig capacity of monocytes via downregulation of class II MHC expression. J Exp Med 1991; 174:15-24.
26. Fiorentino DF, Zlontinik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
27. de Waal MR, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cells clones and resting T cells. J Immunol 1993; 150:4754-65.
28. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81:2964-71.
29. Schandene L, Alonso-Vega C, Willems F et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994; 152:4368-74.
30. + T lymphocytes are regulated by interleukin-10. Immunology 2000; 99:402-10.
31. + T cells. J Immunol 1998; 160:3188-93.
32. Santim AD, Hermonat PL, Ravaggi A et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus- spsecific CD8(+) cytotoxic T lymphocytes. J Virol 2000; 74:4729-37.
33. + T lymphocytes migration. J Immunol 1993; 151:4545-51.
34. Rowbotton AW, Lepper MW, Garland RJ et al. IL-10 induced CD8 cell proliferation. Immunology 1999; 98:80-9.
35. Hollub M, Beran O, Kalanin J, Hnykova J, Spala J, Rozsypal H. CD38 antigen as a marker for immunological follow-up in HIV positive patients. Klin Microbiol Infekc Lek 2004; 10:229-51.
36. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166:1084-97.
37. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leuk Biol 1997; 61:246-57.
38. Cole KE, Strick CA, Paradis TJ et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-21.
39. Herath KB, Jayasuriya H, Ondeyka JG et al. Isolation and structures of novel fungal metabolites as chemokine receptor (CCR2) antagonists. J Antibiot 2005; 58:686-94.
40. Mahad D, Callahan MK, Williams KA et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006; 129:212-23.
41. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19:568-74.
42. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187:875-83.